Bank of Montreal Can lifted its stake in shares of BioLife Solutions Inc (NASDAQ:BLFS) by 5.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 66,805 shares of the medical equipment provider’s stock after buying an additional 3,308 shares during the quarter. Bank of Montreal Can owned about 0.21% of BioLife Solutions worth $1,196,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Wellington Management Group LLP boosted its stake in BioLife Solutions by 82.8% during the first quarter. Wellington Management Group LLP now owns 256,400 shares of the medical equipment provider’s stock worth $2,436,000 after acquiring an additional 116,100 shares in the last quarter. Geode Capital Management LLC lifted its position in BioLife Solutions by 8.8% during the first quarter. Geode Capital Management LLC now owns 152,714 shares of the medical equipment provider’s stock valued at $1,450,000 after purchasing an additional 12,310 shares during the period. Alliancebernstein L.P. lifted its position in BioLife Solutions by 55.8% during the first quarter. Alliancebernstein L.P. now owns 16,200 shares of the medical equipment provider’s stock valued at $154,000 after purchasing an additional 5,800 shares during the period. Russell Investments Group Ltd. lifted its position in BioLife Solutions by 60.9% during the second quarter. Russell Investments Group Ltd. now owns 674,172 shares of the medical equipment provider’s stock valued at $11,006,000 after purchasing an additional 255,139 shares during the period. Finally, Squarepoint Ops LLC bought a new position in BioLife Solutions during the first quarter valued at approximately $501,000. Institutional investors own 46.90% of the company’s stock.
In other BioLife Solutions news, CEO Michael Rice sold 18,750 shares of the stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $23.24, for a total transaction of $435,750.00. Following the completion of the transaction, the chief executive officer now owns 227,096 shares in the company, valued at $5,277,711.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Thomas Girschweiler sold 305,583 shares of the stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $14.50, for a total transaction of $4,430,953.50. The disclosure for this sale can be found here. Insiders have sold 609,799 shares of company stock valued at $10,605,400 over the last ninety days. 22.30% of the stock is currently owned by corporate insiders.
Shares of NASDAQ BLFS opened at $27.68 on Wednesday. The stock has a market cap of $829.48 million, a PE ratio of 432.00, a price-to-earnings-growth ratio of 86.40 and a beta of 1.70. The firm has a fifty day moving average price of $20.94 and a 200-day moving average price of $15.83. BioLife Solutions Inc has a 1 year low of $7.37 and a 1 year high of $27.71.
BioLife Solutions (NASDAQ:BLFS) last posted its earnings results on Thursday, August 6th. The medical equipment provider reported ($0.01) earnings per share for the quarter. The company had revenue of $9.92 million for the quarter, compared to analysts’ expectations of $9.68 million. BioLife Solutions had a net margin of 42.52% and a return on equity of 1.49%. On average, sell-side analysts expect that BioLife Solutions Inc will post 0.03 earnings per share for the current fiscal year.
A number of analysts have commented on BLFS shares. B. Riley upped their target price on shares of BioLife Solutions from $20.00 to $25.50 and gave the company a “buy” rating in a report on Friday, July 10th. Northland Securities reaffirmed a “buy” rating and set a $28.00 target price on shares of BioLife Solutions in a report on Friday, August 7th. BidaskClub raised shares of BioLife Solutions from a “buy” rating to a “strong-buy” rating in a report on Tuesday. Benchmark cut shares of BioLife Solutions from a “buy” rating to a “hold” rating and set a $21.00 target price for the company. in a report on Tuesday, August 11th. Finally, ValuEngine raised shares of BioLife Solutions from a “hold” rating to a “buy” rating in a report on Wednesday, August 19th. One research analyst has rated the stock with a sell rating, one has given a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. BioLife Solutions presently has a consensus rating of “Buy” and an average price target of $22.94.
BioLife Solutions Profile
BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.
See Also: Economic Bubble
Want to see what other hedge funds are holding BLFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioLife Solutions Inc (NASDAQ:BLFS).
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.